RalA signaling pathway as a therapeutic target in hepatocellular carcinoma (HCC)

Molecular Oncology

Volumn 8, Issue 5, 2014, Pages 1043-1053

  Ezzeldin, Mohamad ^a   Borrego Diaz, Emma ^a   Taha, Mohammad ^a   Esfandyari, Tuba ^a   Wise, Amanda L ^a   Peng, Warner ^a   Rouyanian, Alex ^a   Asvadi Kermani, Atabak ^a   Soleimani, Mina ^a   Patrad, Elham ^a   Lialyte, Kristina ^a   Wang, Kun ^a   Williamson, Stephen ^a   Abdulkarim, Bashar ^b   Olyaee, Mojtaba ^a   Farassati, Faris ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

Aurora kinase; Cancer stem cells; FXR; HCC; Ral; RalBP1; Signaling; Treatment

Indexed keywords

AURORA KINASE INHIBITOR; RALA PROTEIN; UNCLASSIFIED DRUG; AURORA KINASE; PROTEIN KINASE INHIBITOR; RAL PROTEIN; RALA PROTEIN, HUMAN; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; DRUG TARGETING; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; LIVER TUMOR; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTO ONCOGENE; STEM CELL; TRANSGENIC MOUSE; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; DRUG EFFECTS; GENE SILENCING; GENETICS; LIVER; LIVER NEOPLASMS; MALE; METABOLISM; MOLECULARLY TARGETED THERAPY; NUDE MOUSE; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE; ANIMAL CELL; CANCER STEM CELL; ENZYME ACTIVATION; ENZYME INHIBITION;

ANIMALIA; MUS MUSCULUS;

ANIMALS; AURORA KINASES; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; GENE SILENCING; HUMANS; LIVER; LIVER NEOPLASMS; MALE; MICE, INBRED C57BL; MICE, NUDE; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; RAL GTP-BINDING PROTEINS; SIGNAL TRANSDUCTION;

EID: 84903534965     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2014.03.020     Document Type: Article

References (31)

1. Ahmed F., Perz J.F., Kwong S., Jamison P.M., Friedman C., Bell B.P. National trends and disparities in the incidence of hepatocellular carcinoma, 1998-2003. Prev. Chronic Dis. 2008, 5:A74.
2. Altekruse S.F., McGlynn K.A., Reichman M.E. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J. Clin. Oncol. 2009, 27:1485-1491.
3. Bodemann B.O., White M.A. Ral GTPases and cancer: linchpin support of the tumorigenic platform. Nat. Rev. Cancer 2008, 8:133-140.
4. Bodempudi V., Yamoutpoor F., Pan W., Dudek A.Z., Esfandyari T., Piedra M., Babovick-Vuksanovic D., Woo R.A., Mautner V.F., Kluwe L., Clapp D.W., De Vries G.H., Thomas S.L., Kurtz A., Parada L.F., Farassati F. Ral overactivation in malignant peripheral nerve sheath tumors. Mol. Cell Biol. 2009, 29:3964-3974.
5. Chiba Y., Sato S., Hanazaki M., Sakai H., Misawa M. Inhibition of geranylgeranyltransferase inhibits bronchial smooth muscle hyperresponsiveness in mice. Am. J. Physiol. Lung Cell Mol. Physiol. 2009, 297:L984-L991.
6. Chien Y., White M.A. RAL GTPases are linchpin modulators of human tumour-cell proliferation and survival. EMBO Rep. 2003, 4:800-806.
7. Clevers H. The cancer stem cell: premises, promises and challenges. Nat. Med. 2011, 17:313-319.
8. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat. Rev. Cancer 2003, 3:11-22.
9. Esfandyari T., Tefferi A., Szmidt A., Alain T., Zwolak P., Lasho T., Lee P.W., Farassati F. Transcription factors down-stream of Ras as molecular indicators for targeting malignancies with oncolytic herpes virus. Mol. Oncol. 2009, 3:464-468.
10. Farassati F., Pan W., Yamoutpour F., Henke S., Piedra M., Frahm S., Al-Tawil S., Mangrum W.I., Parada L.F., Rabkin S.D., Martuza R.L., Kurtz A. Ras signaling influences permissiveness of malignant peripheral nerve sheath tumor cells to oncolytic herpes. Am. J. Pathol. 2008, 173:1861-1872.
11. Farassati F., Yang A.D., Lee P.W. Oncogenes in Ras signalling pathway dictate host-cell permissiveness to herpes simplex virus 1. Nat. Cell Biol. 2001, 3:745-750.
12. Feig L.A. Ral-GTPases: approaching their 15 minutes of fame. Trends Cell Biol. 2003, 13:419-425.
13. Feinstein E. Ral-GTPases: good chances for a long-lasting fame. Oncogene 2005, 24:326-328.
14. Ferro E., Trabalzini L. RalGDS family members couple Ras to Ral signalling and that's not all. Cell Signal 2010, 22:1804-1810.
15. Francipane M.G., Chandler J., Lagasse E. Cancer stem cells: a moving target. Curr. Pathobiol. Reports 2013, 1:111-118.
16. Guo G.L., Santamarina-Fojo S., Akiyama T.E., Amar M.J., Paigen B.J., Brewer B., Gonzalez F.J. Effects of FXR in foam-cell formation and atherosclerosis development. Biochim. Biophys. Acta 2006, 1761:1401-1409.
17. Hagiwara S., Kudo M., Ueshima K., Chung H., Yamaguchi M., Takita M., Haji S., Kimura M., Arao T., Nishio K., Park A.M., Munakata H. The cancer stem cell marker CD133 is a predictor of the effectiveness of S1+ pegylated interferon alpha-2b therapy against advanced hepatocellular carcinoma. J. Gastroenterol. 2010.
18. Heron N.M., Anderson M., Blowers D.P., Breed J., Eden J.M., Green S., Hill G.B., Johnson T., Jung F.H., McMiken H.H., Mortlock A.A., Pannifer A.D., Pauptit R.A., Pink J., Roberts N.J., Rowsell S. SAR and inhibitor complex structure determination of a novel class of potent and specific Aurora kinase inhibitors. Bioorg. Med. Chem. Lett. 2006, 16:1320-1323.
19. Jeng Y.M., Peng S.Y., Lin C.Y., Hsu H.C. Overexpression and amplification of Aurora-A in hepatocellular carcinoma. Clin. Cancer Res. 2004, 10:2065-2071.
20. Kohga, K., Tatsumi, T., Takehara, T., Tsunematsu, H., Shimizu, S., Yamamoto, M., Sasakawa, A., Miyagi, T., Hayashi, N. Expression of CD133 confers malignant potential by regulating metalloproteinases in human hepatocellular carcinoma. J. Hepatol. 52, 872-879.
21. Lee J.S., Chu I.S., Heo J., Calvisi D.F., Sun Z., Roskams T., Durnez A., Demetris A.J., Thorgeirsson S.S. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology 2004, 40:667-676.
22. Lim K.H., Brady D.C., Kashatus D.F., Ancrile B.B., Der C.J., Cox A.D., Counter C.M. Aurora-A phosphorylates, activates, and relocalizes the small GTPase RalA. Mol. Cell Biol. 2009, 30:508-523.
23. McGlynn K.A., London W.T. Epidemiology and natural history of hepatocellular carcinoma. Best Pract. Res. Clin. Gastroenterol. 2005, 19:3-23.
24. Monteiro J., Fodde R. Cancer stemness and metastasis: therapeutic consequences and perspectives. Eur. J. Cancer 2010, 46:1198-1203.
25. Pan W., Bodempudi V., Esfandyari T., Farassati F. Utilizing ras signaling pathway to direct selective replication of herpes simplex virus-1. PLoS One 2009, 4:e6514.
26. Tanaka S., Arii S., Yasen M., Mogushi K., Su N.T., Zhao C., Imoto I., Eishi Y., Inazawa J., Miki Y., Tanaka H. Aurora kinase B is a predictive factor for the aggressive recurrence of hepatocellular carcinoma after curative hepatectomy. Br. J. Surg. 2008, 95:611-619.
27. Teufel A., Staib F., Kanzler S., Weinmann A., Schulze-Bergkamen H., Galle P.R. Genetics of hepatocellular carcinoma. World J. Gastroenterol. 2007, 13:2271-2282.
28. Wang K., Chen Y., Liu S., Qiu S., Gao S., Huang X., Zhang J., Peng X., Qiani W., Zhang J.Y. Immunogenicity of Ra1A and its tissue-specific expression in hepatocellular carcinoma. Int. J. Immunopathol Pharmacol. 2009, 22:735-743.
29. Wolfe A., Thomas A., Edwards G., Jaseja R., Guo G.L., Apte U. Increased activation of Wnt/{beta}-catenin pathway in spontaneous hepatocellular carcinoma observed in farnesoid x receptor knockout mice. J. Pharmacol. Exp. Ther. 2011.
30. Wu J.C., Chen T.Y., Yu C.T., Tsai S.J., Hsu J.M., Tang M.J., Chou C.K., Lin W.J., Yuan C.J., Huang C.Y. Identification of V23RalA-Ser194 as a critical mediator for Aurora-A-induced cellular motility and transformation by small pool expression screening. J. Biol. Chem. 2005, 280:9013-9022.
31. Yin S., Li J., Hu C., Chen X., Yao M., Yan M., Jiang G., Ge C., Xie H., Wan D., Yang S., Zheng S., Gu J. CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. Int. J. Cancer 2007, 120:1444-1450.